Australia markets open in 8 hours 15 minutes

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
163.30-1.62 (-0.98%)
As of 09:45AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close164.92
Open162.99
Bid0.00 x 900
Ask0.00 x 1200
Day's range162.82 - 164.57
52-week range155.72 - 186.69
Volume808,786
Avg. volume6,961,375
Market cap426.945B
Beta (5Y monthly)0.57
PE ratio (TTM)24.26
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.52 (2.69%)
Ex-dividend date17 Feb 2023
1y target estN/A
  • Business Wire

    Johnson & Johnson Reports Q4 and Full-Year 2022 Results

    NEW BRUNSWICK, N.J., January 24, 2023--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johns

  • Business Wire

    Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference

    NEW BRUNSWICK, N.J., January 18, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15th. Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time).

  • Business Wire

    Johnson & Johnson Completes Acquisition of Abiomed

    NEW BRUNSWICK, N.J., December 22, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.